L.L.C. Intervac, Net Worth

The estimated Net Worth of L.L.C. Intervac, is at least 46.6 百万$ dollars as of 18 April 2011. L Intervac owns over 7,000 units of Emergent Biosolutions Inc stock worth over 46,455,531$ and over the last 17 years L sold EBS stock worth over 163,170$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

L Intervac EBS stock SEC Form 4 insiders trading

L has made over 1 trades of the Emergent Biosolutions Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently L sold 7,000 units of EBS stock worth 163,170$ on 18 April 2011.

The largest trade L's ever made was selling 7,000 units of Emergent Biosolutions Inc stock on 18 April 2011 worth over 163,170$. On average, L trades about 259 units every 0 days since 2008. As of 18 April 2011 L still owns at least 6,136,794 units of Emergent Biosolutions Inc stock.

You can see the complete history of L Intervac stock trades at the bottom of the page.

What's L Intervac's mailing address?

L's mailing address filed with the SEC is C/O EAST-WEST RESOURCES CORPORATION, 12001 GLEN ROAD, POTOMAC, MD, 20854.

Insiders trading at Emergent Biosolutions Inc

Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over 131,382,266$ worth of Emergent Biosolutions Inc stock and bought 4,647 units worth 138,981$ . The most active insiders traders include Seamus Mulligan、Fuad El Hibri、Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of 147,206$. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth 61,100$.

What does Emergent Biosolutions Inc do?

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent

Complete history of L Intervac stock trades at Emergent Biosolutions Inc

Emergent Biosolutions Inc executives and stock owners

Emergent Biosolutions Inc executives and other stock owners filed with the SEC include:

• Robert Kramer,
  President, Chief Executive Officer, Director
• Fuad El-Hibri,
  Executive Chairman of the Board
• Robert G. Kramer,
  CEO, Pres & Exec. Director
• Richard Lindahl,
  Chief Financial Officer, Executive Vice President, Treasurer
• Atul Saran,
  Executive Vice President, Corporate Development, General Counsel and Corporate Secretary
• Adam Havey,
  Executive Vice President - Business Operations
• Fuad El-Hibri,
  Founder & Exec. Chairman
• Richard S. Lindahl,
  Exec. VP, CFO & Treasurer
• Adam R. Havey,
  Exec. VP & COO
• Atul Saran,
  Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel
• Seamus Mulligan,
  Director
• Ronald Richard,
  Lead Independent Director
• Zsolt Harsanyi,
  Independent Director
• Louis Sullivan,
  Independent Director
• Jerome Hauer,
  Independent Director
• George Joulwan,
  Independent Director
• Kathryn Zoon,
  Independent Director
• Sue Bailey,
  Independent Director
• Marvin White,
  Director
• Robert Burrows,
  Vice President, Investor Relations
• Sean Kirk,
  Executive Vice President, Manufacturing and Technical Operations
• Katherine Strei,
  Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
• Katherine Strei,
  Exec. VP of HR & Chief HR Officer
• Nina DeLorenzo,
  Sr. VP of Global Communications & Public Affairs
• Lynn Kieffer,
  VP of Corp. Communications
• Howard Anderson,
  Sr. VP & Chief Information Officer
• Karen L. Smith,
  EVP, Chief Medical Officer
• John Niederhuber,
  Director
• Daniel Abdun Nabi,
  SVP Corp Aff, GC & Secretary
• L.L.C. Bio Pharm,,
  10% owner
• Stephen Lockhart,
  SVP Product Development
• L.L.C. Intervac,,
  10% owner
• Steven Chatfield,
  President, EPD UK & CSO
• R Don Elsey,
  VP Finance, CFO & Treasurer
• Barry Labinger,
  EVP, Biosciences Div.
• Denise Esposito,
  SVP Legal Affairs & GC
• L.L.C. Biologika,,
  
• Biologic Products, Inc. Mic...,
  
• Kyle Keese,
  SVP Mktg & Comm.
• Joe M Allbaugh,
  Director
• Mauro Gibellini,
  SVP Corporate Dev.
• Investments Ltd Microscience,
  10% owner
• Shahzad Malik,
  Director
• Edward Arcuri,
  EVP & COO
• Thomas Zink,
  SVP & CMO
• Robert Calvin Myers,
  
• Joseph C Papa,
  President and CEO
• Jennifer Lynne Fox,
  EVP, Ext Aff, GC, Corp Sec
• Keith Katkin,
  Director
• Coleen Glessner,
  EVP, Quality & Ethics, and CPL
• Sujata Tyagi Dayal,
  Director
• Paul Anthony Williams,
  SVP, Products Business
• William Hartzel,
  SVP, Bioservices
• Neal Franklin Fowler,
  Director
• Donald W De Golyer,
  Director